查看文章

As healthcare expenses are escalating in many countries, the sector faces a new challenge of becoming more cost efficient. There is an urgent need for more accurate data on the costs of healthcare procedures. The cost of Positron Emission Tomography (PET) with [¹⁸F]-fludeoxyglucose (¹⁸F-FDG) studies is mainly influenced by the price of the radiopharmaceutical, which may vary throughout Europe from 300 to 500 Euro per patient dose (370 MBq). The aim of the current study is to conduct an activity-based costing (ABC) estimation of ¹⁸F-FDG production in Europe to better identify the different cost components and to analyse their relative contribution to the total cost.

Financial data were collected on capital expense and global operating costs through interviews with industry experts, PET centre managers …